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Abstract 
 
Small interfering RNAs (siRNAs) show potential for the treatment of a wide variety of 
pathologies with a known genetic origin through sequence-specific gene silencing. However, 
siRNAs do not have favorable drug-like properties and need to be packaged into nanoscopic 
carriers that are designed to guide the siRNA to the cytoplasm of the target cell. In this 
report biodegradable cationic dextran nanogels are used to deliver siRNA across the 
intracellular barriers. For the majority of non-viral siRNA carriers studied so far, endosomal 
confinement is identified as the most prominent hurdle, limiting the full gene silencing 
potential. Thus, there is a major interest in methods that are able to enhance endosomal 
escape of siRNA to improve its intracellular bioavailability. Photochemical internalization 
(PCI) is a method that employs amphiphilic photosensitizers to destabilize endosomal 
vesicles. We show that applying PCI at a later time-point post-transfection significantly 
prolonged the knockdown of the target protein only in case the siRNA was carried by 
nanogels and not when a liposomal carrier was used. Combining siRNA nanogels and PCI 
creates new possibilities to prolong gene silencing by using intracellular vesicles as depots 
for siRNA and applying PCI at the time when maintaining the RNAi effect becomes critical. 
 
 
Graphical abstract 
 
Combining siRNA nanogels and photochemical internalization (PCI) creates new possibilities 
to prolong gene silencing by using intracellular vesicles as depots and applying PCI at the 
time when maintaining the RNAi effect becomes critical. 
 
 
 
 
Keywords 
 
siRNA, nanogels, transfection, endosomal escape, photochemical internalization, prolonged 
effect 
 
 
Abbreviations 
 
AEMA, 2-aminoethyl methacrylate hydrochloride; AF647, alexa fluor® 647; dex-HEMA, 
dextran hydroxyethyl methacrylate; dex-MA, dextran methacrylate; DEPC, diethyl 
pyrocarbonate; DLS, dynamic light scattering; DS, degree of substitution; DsiRNA, Dicer 
substrate siRNA; EGFP, enhanced green fluorescent protein; Huh-7, human hepatoma-7; PCI, 
photochemical internalization; PS, photosensitizer; RNAi, RNA interference; siRNA, small 
interfering RNA; TMAEMA, [2-(methacryloyloxy)-ethyl]trimethylammonium chloride. 
 
Introduction 
 
Since the discovery of RNA interference (RNAi) [1], intensive research on RNAi therapeutics 
and their potential applications has led to an astonishing progress in just over a single 
decade. This resulted in a fast transition of promising lead siRNA candidates from in vitro 
tests to clinical trials [2-4]. Advances are made, both in the area of siRNA design [5-9] and 
siRNA delivery. New formulation strategies emerge, designed to overcome intra- and 
extracellular hurdles and to improve the fraction of the administered siRNA dose that 
eventually reaches the cytoplasm of the target cell [3,10-12].  
One of the limitations of non-viral carriers for synthetic siRNA delivery, especially 
when long-term treatment is advised, is the transient nature of the gene silencing effect as a 
result of cell division and intracellular siRNA degradation  [13-16]. On the other hand, major 
concerns are raised with regard to adverse effects of siRNA therapeutics, such as unwanted 
immune activation [17], off-target silencing [18] and saturation of the RNAi machinery [19]. 
As these effects are concentration-dependent it is obvious that delivery of siRNA requires 
rigorous control over the intracellular siRNA concentrations [13,20]. As a consequence, 
delivery strategies that are able to control the amount of siRNA that is released in the 
cytoplasm as a function of time could be of interest to obtain a prolonged gene silencing 
and/or to minimize side-effects. While the magnitude of target gene (or protein) 
suppression, relative to a control sample, may be a good indicator for the success of an 
siRNA treatment, looking at the time-window during which the siRNA therapeutic 
intervention is able to keep the intracellular protein titers below a certain threshold, is 
perhaps a better parameter to decide on the efficacy of the delivery strategy [14]. The 
duration of the silencing effect will eventually strongly determine the dosage frequency in 
chronic clinical therapy.  
During the last decade, an increasing number of publications describes nanoscopic 
hydrogels as drug delivery carriers, though only a few reports are available on nanogels for 
siRNA delivery [21]. In this report, cationic dextran nanogels loaded with siRNA are studied 
[22]. Following in vitro transfection of cells with siRNA loaded cationic nanogels (Fig. 1) we 
observed that a major fraction of the internalized nanogels is trafficked towards acidified 
vesicles (presumably endolysosomes), which may limit the full potential of RNAi [22]. Here 
we set out to evaluate if these intracellular vesicles, packed with siRNA nanogels, can be 
used as a siRNA depot from which siRNA can be released at the desired time in order to 
prolong the gene silencing effect. In this way the siRNA dose that is taken up by the target 
cells could be far more efficiently deployed. 
As a trigger to induce endosomal escape of siRNA, we applied photochemical 
internalization (PCI). PCI is a technique that promotes endosomal escape of a variety of 
therapeutic molecules, such as chemotherapeutics, proteins and nucleic acids and has 
already proven to enhance gene transfer and RNAi silencing with viral and non-viral 
nanocarriers. Upon incubation with cells, the photosensitizer (PS) predominantly localizes in 
the endosomal membrane. Excitation of the PS to its singlet state can be followed by 
intersystem crossing to its triplet state, of which the energy may be used in photochemical 
or photophysical reactions. This results in the emergence of reactive oxygen species (ROS), 
predominantly singlet oxygen (1O2
 
) that may catalyze the oxidation of amino acids, 
unsaturated fatty acids and cholesterol. Due to its short diffusion range (~10-20 nm) and its 
short lifetime (0.01-0.04 µs), singlet oxygen initiates oxidation reactions mainly in the local 
production area [23-26]. This oxidative damage eventually breaks down the endosomal 
barrier, allowing the transition of internalized nanosized matter into the cytoplasm. 
 
 
 
Fig. 1. Chemical structures of dextran hydroxyethyl methacrylate (dex-HEMA), [2-
(methacryloyloxy)-ethyl]trimethylammonium chloride (TMAEMA), 2-aminoethyl 
methacrylate hydrochloride (AEMA) and dextran methacrylate (dex-MA). Radical 
polymerization results in the formation of a hydrogel network, which is shown for dex-
HEMA-co-TMAEMA. To prepare cationic nanogels dex-(HE)MA is copolymerized with 
TMAEMA (and/or AEMA) by a mini-emulsion photopolymerization (see Supplementary 
Information) [22,27]. While dex-HEMA based nanogels are biodegradable (through 
hydrolysis of the carbonate ester) dex-MA based nanogels are not as it does not contain a 
labile ester bond between the methacrylate moiety and the dextran backbone [22,27,28]. 
Nanogels are loaded with siRNA by rehydrating a weighed amount of nanogel lyophilizate 
with HEPES buffer and mixing the resulting dispersion with an equal volume of siRNA 
solution. Dex-HEMA and dex-MA are prepared with varying degree of substitution (DS), 
being the number of (HE)MA crosslinks per 100 glucopyranose units. 
 
 
Materials and methods 
 
siRNA duplexes 
 
Twenty-one nucleotide siRNAs targeting the pGL3 firefly luciferase gene (siLUC), the 
enhanced green fluorescent protein (siEGFP) and a universal negative control duplex 
(siCONTROL) were purchased from Eurogentec (Seraing, Belgium) and stored in 20 µM 
aliquots in DEPC treated water (-20°C). siLUC: sense strand = 5’-
CUUACGCUGAGUACUUCGAtt-3’ ; antisense strand = 5’-UCGAAGUACUCAGCGUAAGtt-3’. 
siEGFP: sense strand = 5’-CAAGCUGACCCUGAAGUUCtt-3’ ; antisense strand = 5’-
GAACUUCAGGGUCAGCUUGtt-3’. siCONTROL: sense strand = 5’-
UGCGCUACGAUCGACGAUGtt-3’ ; antisense strand = 5’-CAUCGUCGAUCGUAGCGCAtt-3’. 
Dicer substrate RNAs (DsiRNAs), chemically modified, targeting the EGFP gene (DsiEGFP) and 
a universal negative control with the same modification pattern (DsiNC-1) were provided by 
Integrated DNA technologies (IDT, Leuven, Belgium). DsiEGFP: sense strand = 5’-
pACCCUGAAGUUCAUCUGCACCACcg-3’ ; antisense strand = 5’-
pCGGUGGUGCAGAUGAACUUCAGGGUCA-3’. DsiNC-1: sense strand = 5’- 
pCGUUAAUCGCGUAUAAUACGCGUat-3’ ; antisense strand = 5’-pAUACGCGUAUUAU-
ACGCGAUUAACGAC-3’. Lower case bold letters represent 2’-deoxyribonucleotides, capital 
letters are ribonucleotides and underlined capital letters are 2’-O-methylribonucleotides. 
Lyophilized DsiRNAs were dissolved in HEPES 30 mM pH 7.5 supplemented with 100 mM KAc 
(100 mM), annealed and stored at -20°C. For fluorescence microscopy experiments, a green 
fluorescent siRNA duplex was ordered from Dharmacon (siGLO® green transfection 
indicator). 
 
Preparation of cationic dextran nanogels and loading with siRNA 
 
Cationic dextran nanogels (dex-HEMA-co-TMAEMA) were prepared using the UV induced 
emulsion photopolymerization as described in our previous work [22], with minor 
adjustments. Dex-HEMA (65 mg) was dissolved in a solution containing 40 µL irgacure 1% 
(w/v), 80 µL TMAEMA (75% w/v) and 80 µL HEPES buffer (pH 7.4, 20 mM).  The obtained 
dex-HEMA solution was emulsified in 5 mL pre-cooled mineral oil, supplemented with 5% 
(v/v) of ABIL EM 90 as emulsifier. Following sonification (Branson sonifier, 30 s - 20%), the 
emulsion was exposed to UV light during 15 min under cooling (~4°C). The prepared 
nanogels were obtained in pure form by precipitation with aceton:hexane (1:1) and 
centrifugation. After washing, the precipitate was redispersed in 5 mL distilled water and 
traces of organic solvent were removed by vacuum evaporation. To assure long-term 
stability, the nanogels were lyophilized and stored desiccated. Note that for the preparation 
of the dex-MA nanogels the same protocol was followed using dex-MA instead of dex-HEMA. 
The thus obtained nanogels were subsequently loaded with siRNA (‘post-loading’). 
Therefore a stock dispersion of nanogels (~2 mg/mL) was prepared in ice-cooled HEPES 
buffer and sonicated to loosen the gel particles (20 s, 10% output power). From this stock 
dispersion, dilutions were prepared according to the experimental needs. Subsequently, 
equal volumes of nanogels and siRNA were mixed at room temperature and left to stand at 
room temperature for ≥ 15 min to allow complexation. 
Fluorescent labelling of nanogels was performed by copolymerization of dex-MA (DS 
5.9) with a 4:1 molar ratio of TMAEMA:AEMA. The nanogels were fluorescently tagged by 
incubating them with Alexa Fluor® 647 (AF647) succinimidyl ester (Molecular Probes), 
followed by extensive dialysis against distilled water (Spectra/Por® Float-A-Lyzer® 100.000 
MWCO) to remove unreacted dye. 
 
 
Dynamic light scattering (DLS) and zeta-potential 
 
Nanogel sizes, polydispersity and surface charge were determined by dynamic light 
scattering (DLS) and zeta-potential measurements respectively, using a Zetasizer Nano ZS 
(Malvern, Worcestershire, UK), operating with Dispersion Technology Software (DTS). The 
samples were equilibrated at 25°C prior to measurement and measurement settings were 
set on automatic. To screen the degradation of the nanogels, nanogel suspensions (500 
µg/mL) were prepared in respectively 20 mM HEPES buffer (pH 7.4) in a low volume cuvette 
that was subsequently sealed with parafilm. The nanogel suspensions were kept at 37°C and 
the intensity of the scattered light was measured every 5 minutes. Each measurement time 
point consisted of 6 runs, with 5 s per run. 
 
Cell lines and culture conditions 
 
All cellular experiments were performed on Huh-7 hepatoma cells. The wild-type cells are 
denoted as Huh-7_wt. Huh-7_LUC cells stably express the firefly and renilla luciferase gene 
[22]. Huh-7_EGFP cells stably produce the enhanced green fluorescent protein [27]. All cells 
are grown in DMEM:F12, supplemented with 2 mM glutamine, 10% heat-inactivated fetal 
bovine serum (FBS, Hyclone) and 100 U/mL penicilline/streptomycine at 37°C in a humidified 
atmosphere containing 5% CO2. 
 
Photochemical internalization 
 
The photosensitizer (PS) meso-tetraphenylporphine disulfonate (TPPS2a) was kindly provided 
by Dr. A. Høgset (PCI Biotech, Oslo, Norway). The PS was protected from light and stored at 
4°C until use. Activation of the PS occurred by exposure to blue light (375 nm – 450 nm) 
emitted by LumiSource (Osram 18W/67, 13 mW/cm2, PCI Biotech, Oslo, Norway).  
 
Luciferase gene silencing 
 
Two days before transfection, Huh-7_LUC cells were seeded in 96-well plates (1 x 104 cells 
per well). For transfection, first 90 µL of pre-heated OptiMEM (37°C) was pipetted on the 
cells and subsequently 10 µL of a siRNA loaded nanogel dispersion (in HEPES buffer) was 
added to the cells in each well (20 pmol of siRNA). After 4 h incubation (37°C), the nanogels 
were removed from the cells and replaced with 150 µL pre-heated cell culture medium. This 
transfection protocol was performed in duplicate (plate 1 and plate 2 respectively) for every 
sample tested. Twenty-four hours later, the cells on plate 1 were lysed with 20 µL passive 
lysis buffer (Promega, Leiden, The Netherlands). Firefly and renilla luciferase activities were 
determined with the Promega Dual-Luciferase® Reporter Assay. For luciferase analysis we 
used a GloMaxTM 96 luminometer with two injectors. Briefly, 10 µL of cell lysate was mixed 
with 50 µL firefly luciferase substrate and after a 2 s delay, firefly luminescence was 
integrated during 10 s (relative light units or RLU). Subsequently, 50 µL of renilla luciferase 
substrate in Stop & Glo Buffer (Promega) was added and again after 2 s renilla luminescence 
was quantified during a 10 s time interval. For each sample, the ratio of firefly luminescence 
to renilla luminescence was calculated. The ratios obtained with siLUC nanogels were 
compared to the ratios obtained with siCONTROL nanogels and expressed as remaining 
luciferase expression (%).  
The cells on plate 2 were trypsinized with 100 µL trypsin/EDTA (0.25%) and replated 
in 5 separate 96-well plates. Four of these plates are analyzed for luciferase expression on 
day 2 till day 5 following transfection. On day 5, the trypsinization step was repeated on the 
remaining 96-well plate in order to avoid overgrowth of the cells and to maintain the cells in 
a state of active cell division. Luciferase expression was additionally analyzed at day 6 and 
day 7. 
 
 
EGFP gene silencing 
 
EGFP silencing with DS 2.5 nanogels 
Two days before transfection, 7.5 x 104 Huh-7_EGFP cells were seeded in 12-well plates. At 
the day of transfection, the culture medium was replaced with 900 µL pre-heated OptiMEM. 
DS 2.5 siEGFP nanogel complexes were prepared in HEPES buffer (~20 min incubation at 
room temperature) and added to the wells to obtain a final volume of 1 mL. The nanogel and 
siEGFP concentration on the cells eventually equaled 60 µg/mL and 75 pmol/mL 
respectively. As controls, ‘empty’ nanogels or nanogels loaded with siCONTROL and siLUC 
were included in the transfection experiment. After 5 h incubation at 37°C, the transfection 
medium was replaced with 2 mL of complete cell culture medium. Five days post-
transfection, the cells were washed with PBS and collected for flow cytometry by 
trypsinization (500 µL trypsin/EDTA 0.25% per well, followed by dilution in 5 mL cell culture 
medium). After centrifugation (1200 rpm, 7 min) the cell pellet was resuspended in 300 µL 
flow buffer and kept on ice until flow analysis. The cells were analyzed using a Beckman 
Coulter Cytomics FC500 flow cytometer. Dead cells were discriminated from viable cells by 
the addition of propidium iodide (Invitrogen). The data were analyzed using Beckman 
Coulter CXP analysis software. 
 
Dose response EGFP silencing with DS 5.2 cationic nanogels 
Huh-7_EGFP cells were seeded in 24-well plates (3 x 104 cells per well). Two days after 
seeding, the cells were transfected with 50 µg/mL nanogels (500 µL in OptiMEM) during 4 h 
after which the medium was replaced with 500 µL of fresh complete cell culture medium. 
We verified for the DS 5.2 nanogels that 4 h incubation with the cells was the optimal 
incubation time. Longer incubation did not improve the RNAi activity but rather induced 
more cytotoxic effects (data not shown). The amount of siEGFP per well was varied between 
0.025 pmol and 125 pmol. Nanogels that complex siLUC were used as a control. At day 3 
post-transfection, the cells were prepared for flow cytometry by trypsinization (250 µL 
trypsin/EDTA 0.25% per well, followed by dilution in 1 mL cell culture medium). After 
centrifugation (1200 rpm, 7 min) the cell pellet was resuspended in 200 µL flow buffer and 
kept on ice until flow cytometry analysis as explained above. 
 
EGFP gene silencing kinetics 
Huh-7_EGFP cells were seeded in 24-well plates at a density of 5 x 104 cells per well. Twenty-
four hours later, the cells were incubated during 4 h with DS 2.5, DS 5.2 and DS 8.9 nanogels 
(50 µg/mL), loaded with siEGFP or siLUC (50 pmol per well) in a final volume of 500 µL 
(OptiMEM). Lipofectamine™RNAiMAX complexes were prepared in OptiMEM and included 
in the transfection experiment (1.56 µL RNAiMAX stock per well). For all samples, the 
transfection was performed in duplicate. Subsequently, the transfection medium was 
replaced with 500 µL cell culture medium. EGFP expression was quantified at different time-
points post-transfection. At every time-point, the cells in the duplicate transfection were 
again replated in two new 24-well plates (1:3 diluted) to be analyzed/replated at the next 
time-point. 
 
Silencing EGFP studied by fluorescence microscopy 
1.5 x 104 Huh-7_EGFP cells were grown on Lab-Tek™ II chambered cover glasses (Nalge Nunc 
International, Rochester, NY) two days pre-transfection. As described above, the 
siRNA:nanogel complexes were prepared in HEPES buffer as a 10x stock dispersion. The 
transfection was performed by incubating the cells during 4 h with 50 µg/mL DS 5.2 
nanogels, loaded with 40 pmol siEGFP in a final volume of 400 µL OptiMEM and after this 
incubation period, the remaining complexes were removed and 400 µL of fresh cell culture 
medium was added per well.  The same controls as indicated in the above paragraph were 
used. After 96 h, the cells were washed with PBS and fixed in 4% paraformaldehyde solution 
(20 min incubation at RT). Subsequently, after three additional washing steps with PBS, the 
cover glasses were mounted with Vectashield® DAPI mounting medium (Vector Labs). EGFP 
expression was visualized by fluorescence microscopy using a Nikon EZC1-si confocal 
scanning module installed on a motorized Nikon TE2000-E inverted microscope (Nikon 
Benelux, Brussels, Belgium) with open pinhole setting. 
 
Influence of photochemical internalization on EGFP gene silencing kinetics 
The effect of PCI on the silencing duration was evaluated in three distinct protocols where 
PCI was conducted at the day of transfection (PCI t0), two days or six days post-transfection 
(PCI t2 and PCI t6 respectively). More details on the protocol time-scale can be found in 
supplementary information Fig. S5-6. For the transfection, 5 x 104 cells were seeded in 24-
well plates and left to grow for 48 h. Transfection of the cells (in 500 µL OptiMEM) was 
performed with DS 5.2 cationic nanogels at varying concentration. The amount of siRNA 
(siEGFP and siLUC) per well was 50 pmol. Reminiscent of previous transfections, an 
incubation period of 4 h with the cells was respected.  
 
 
Photochemical internalization studied by fluorescence microscopy 
 
Huh-7_wt cells transfected with dex-HEMA-co-TMAEMA (DS 3.2) nanogels were visualized 
by fluorescence microscopy respectively before and after they were treated with PCI. For 
this experiment 12.5 x 104 Huh-7_wt cells were seeded in Lab-Tek™ II chambered 
coverglasses (Nalge Nunc International, Rochester, NY), two days before transfection. One 
day pre-transfection, PS was added to half of the wells (0.4 µg/mL). At the day of 
transfection, the PS was removed and the cells were washed with PBS. Cationic nanogels 
were loaded with fluorescent siGLO® in hepes buffer as indicated earlier and incubated with 
the cells in 400 µl OptiMEM. The final concentration of nanogels and siGLO® was 25 µg/mL 
and 200 pmol/mL respectively. After 3 h incubation, the remaining complexes were removed 
and replaced with complete cell culture medium (37°C). One hour of incubation later, the 
culture chambers were illuminated with LumiSource® (45s). The cells were placed at 37°C for 
another 36 h, protected from light. Afterwards, the cell-bound siGLO® fluorescence was 
quenched by treatment with 0.4% trypan blue (8 min) and after washing with PBS the cells 
were fixed with 4% paraformaldehyde (20 min, RT). Following 3 washing steps with PBS, the 
cells were mounted with Vectashield® DAPI Mounting Medium (Vector Labs, UK) and kept at 
4°C (dark) until fluorescence imaging. 
 
Statistical analysis 
 
All transfection measurements are minimally performed in triplicate and expressed as mean 
± SD. A paired t-test was conducted to assess the statistical significance in the PCI 
experiments. 
 
 
Results and Discussion 
 
Cationic dextran nanogels with different crosslink density were obtained through the use of 
dex-(HE)MA with a different DS. The size and zeta-potential of the nanogel batches can be 
found in Table 1. By dynamic light scattering (DLS) we showed that dex-HEMA nanogels 
dispersed in buffer gradually degrade while dex-MA nanogels do not, as expected 
(supplementary information_Fig. S1). 
A good complexation of the negatively charged siRNA to the cationic dex-HEMA-co-
TMAEMA nanogels is a prerequisite to successfully deliver siRNA across the plasma 
membrane into the cytosol. To evaluate this, the nanogel samples listed in Table 1 were 
titrated with siRNA and the resultant zeta-potential of the siRNA loaded nanogels was 
measured. Clearly, the loading of the nanogels with siRNA is reflected in the zeta-potential 
value as can be seen in the typical sigmoidal curves that are obtained (Fig. 2). 
 
 
Table 1. Size and surface charge of the dex-HEMA-co-TMAEMA nanogels. Analysis was 
performed in HEPES buffer (pH 7.4, 20 mM) with a final nanogel concentration of 0.2 mg/mL. 
Values are the average ± SD of at least 3 measurements on the same sample. 
 
dextran sample dh (nm) PDI 
a ζ-potential (mV) 
dex-HEMA DS 2.5 254 ± 5 0.081 ± 0.055 24.1 ± 0.7 
dex-HEMA DS 3.2 267 ± 8 0.274 ± 0.026 27.9 ± 0.9 
dex-HEMA DS 5.2 212 ± 1 0.106 ± 0.029 24.8 ± 0.4 
dex-HEMA DS 8.9 207 ± 1 0.137 ± 0.034 17.1 ± 0.7 
dex-MA DS 3.4 219 ± 5 0.105 ± 0.012 30.2 ± 0.8 
dex-MA DS 5.9 195 ± 8 b 0.196 ± 0.014 27.2 ± 0.6 
ahydrodynamic diameter, bdex-MA-co-TMAEMA modified with 20% AEMA for fluorescent 
labeling with Alexa Fluor®
 
647, PDI = polydispersity index, DS = degree of (HE)MA substitution 
 
 
Fig. 2. Titration of nanogel dispersions with increasing amounts of siRNA. From left to right: 
DS 8.9 (▲) – DS 2.5 (▼) – DS 5.2 (●) – DS 3.4 (■). Line graphs represent a Boltzmann 
sigmoidal fit (Microcal Origin v 5.0). Measurements are performed at 25°C in HEPES buffer 
20 mM, pH 7.4. The zeta-potential of the siRNA loaded nanogels was normalized to the zeta-
potential of the unloaded nanogels. 
 
Apparently, the nanogels behave differently in their siRNA complexation. Nanogels with DS 
5.2 (dex-HEMA) and DS 3.4 (dex-MA) display a decrease in zeta-potential at substantially 
higher siRNA amounts compared with DS 2.5 and DS 8.9 nanogels. It indicates that the latter 
nanogels are able to load less siRNA molecules per µg nanogel lyophilisate. This may be due 
to e.g. some  dex-HEMA hydrolysis during nanogel production (especially in case of the lowly 
crosslinked DS 2.5 nanogels). Also, the lower zeta-potential in case of the DS 8.9 nanogels 
(see Table 1) may explain the lower siRNA loading capacity of these nanogels. Alternatively, 
their high crosslinking degree could potentially exclude the siRNAs from the core of the 
nanogels leading to a decrease in the maximal siRNA loading capacity. 
 
 
Fig. 3. Gene silencing kinetics by siRNA loaded dex-HEMA-co-TMAEMA nanogels, as a 
function of the DS of the nanogels (A: DS 2.5, B: DS 5.2, C: DS 8.9)  and siRNA complexed 
with Lipofectamine™RNAiMAX (D). To allow a more easy comparison of the luciferase gene 
silencing kinetics, the data obtained with different nanogel concentrations (30 µg/mL till 70 
µg/mL) and lipofectamine™RNAiMAX (all 3 concentrations tested) were averaged and 
summarized in (E). Transfection experiments were performed in a 96-well plate format with 
a fixed amount of siRNA (20 pmol) per well. Data points represent average values ± SD (n=4). 
 
 
The RNAi activity of the siRNA loaded nanogels (Table 1, Fig. 3) was subsequently evaluated 
in Huh-7 cells, stably expressing both firefly and renilla luciferase (Huh-7_LUC cells) [22]. The 
sequence of the active siRNA was designed to selectively reduce firefly luciferase expression. 
The siRNA induced knockdown of firefly luciferase was normalized to the renilla luciferase 
expression which should not be affected by the active siRNA (see also supplementary 
information). Luciferase expression was followed during one week after applying siRNA 
nanogels on the cells (Fig. 3). To maintain the cells in a state of active cell division and 
prevent cellular overgrowth, we replated the cells at day 1 and day 5 post-transfection. As a 
positive control, the RNAi gene silencing induced by Lipofectamine™RNAiMAX was evaluated 
as well.  
Fig. 3 (A-C) demonstrates a substantial downregulation of firefly luciferase for all 
nanogels tested. Nanogels with a higher crosslink density (DS 8.9) showed less gene silencing 
(< 50% knockdown, Fig. 3C). Non-degradable dex-MA nanogels were not able to silence the 
firefly luciferase gene to an appreciable extent (supplementary information_Fig. S2). Note 
that the higher the DS of the nanogels the longer it takes to become degraded, while dex-
MA based nanogels do not degrade at all [27]. It can be hypothesized that the DS 8.9 
nanogels, when compared to DS 2.5 and DS 5.2, degrade too slow which could have its 
implications on the intracellular release of siRNA. Also, Table 1 and Fig. 2 showed a 
significantly lower zeta-potential and siRNA complexation capacity for the DS 8.9 nanogels; 
the lower positive surface charge of the DS 8.9 nanogels may result in a less efficient cellular 
internalization. Less uptake of DS 8.9 nanogels by Huh-7 cells could indeed be confirmed by 
flow cytometry (data not shown) and is therefore one of the reasons which explains the 
lower gene silencing by DS 8.9 nanogels. 
None of the siRNA loaded nanogels was able to maintain sufficient gene silencing up 
to 7 days. The DS 2.5 nanogels (Fig. 3A), DS 5.2 nanogels (Fig. 3B) and 
Lipofectamine™RNAiMAX (Fig. 3D) achieved a maximal gene silencing of > 75% two days 
post-transfection. This level of gene suppression was maintained for an additional 24 h at 
most. Five days post-transfection, on average gene expression has recovered to ~50% 
compared to control, and seven days post-transfection, in most cases little gene suppression 
remains. From these data we conclude that the initial crosslink density of the nanogels 
apparently has an important effect on the extent of gene silencing though has little to no 
influence on the duration of the silencing.  
We next evaluated the silencing of enhanced green fluorescent protein (EGFP) stably 
expressed in Huh-7_EGFP cells [27]. Fig. 4A-C proves that dextran nanogels loaded with 
siRNA targeting the EGFP gene, were able to reduce the EGFP expression significantly. Fig. 4 
also confirms the sequence-specificity of the downregulation effect, since none of the 
controls, i.e. empty nanogels and nanogels loaded with either a universal control siRNA 
(siCONTROL) or an irrelevant but validated siRNA (siLUC), reduced EGFP expression. A dose 
response experiment with DS 5.2 nanogels demonstrated a clear influence of the amount of 
siRNA used on the knockdown efficiency with an eventual IC50 value ~1 pmol/mL siRNA 
under the experimental conditions (Fig. 4B).  A time-dependent gene silencing experiment 
(Fig. 4D) lead to the observation that the extent of EGFP silencing significantly differs 
between the nanogels while the recovery of the EGFP expression is rather similar for all 
nanogels, in agreement with what we observed in the luciferase knockdown experiments in 
Fig. 3. Taken together from the data in Fig. 3 and Fig. 4 we assume that the gene silencing 
kinetics is independent on the dex-HEMA nanogel characteristics and is most likely governed 
by cell division [14]. 
 
 
 
 
Fig. 4. (A) EGFP silencing by dex-HEMA DS 2.5 nanogels (60 µg/mL). Respectively empty 
nanogels (i.e. without siRNA) and nanogels loaded with control siRNA (siCONTROL, siLUC) or 
active siRNA (siEGFP) were used. The amount of siRNA added per well was 75 pmol per 7.5 x 
104 seeded cells in 12-well format and the EGFP expression was quantified 5 days post-
transfection. (B) EGFP expression following transfection with dex-HEMA DS 5.2 nanogels (50 
µg/mL) loaded with increasing amounts of siRNA. Data are shown as the amount of EGFP 
fluorescence in cells exposed to siEGFP nanogels relative to EGFP expression in cells exposed 
to siLUC nanogels (in %). Expression of EGFP was quantified 72 h post-transfection and 
transfection was performed in 24-well plates with 3 x 104 seeded cells per well. (C) Visual 
control of EGFP silencing by DS 5.2 nanogels. In the left panel the cell nuclei are shown after 
staining with DAPI and the right panel shows the EGFP expression. (D) Time-dependent EGFP 
suppression in cells exposed to siEGFP loaded dex-HEMA-co-TMAEMA nanogels and 
siEGFP/lipofectamine™RNAiMAX complexes. The concentration of nanogels was fixed to 50 
µg/mL and the amount of siRNA per well equalled 50 pmol (24-well plate). 
 
 
Although siRNA loaded dex-HEMA nanogels significantly suppress gene expression in 
hepatoma cells we did observe that the majority of internalized siRNA-nanogels accumulates 
in acidified vesicles, which significantly hampers the cytoplasmic delivery of siRNA [22]. We 
hypothesize that following cellular uptake only a small fraction of the siRNA molecules 
complexed to the nanogels reaches the cell cytoplasm and becomes available for 
incorporation into the RNAi pathway [22]. Indeed, also other reports in literature suggest 
that only a minor fraction of the siRNA transported across the cellular membrane by non-
viral carriers is eventually responsible for the RNAi effect [29-32].  
To improve the release of siRNA into the cytosol it is thus imperative to stimulate the 
escape of siRNA loaded nanogels from the endosomal compartment into the cytoplasm of 
the cell. Our previous data showed that photochemical internalization (PCI) can enhance the 
extent of gene silencing obtained with dex-HEMA nanogels [22]. PCI involves the use of 
amphiphilic photosensitizers (PS) that preferentially localize in the membrane of endocytic 
vesicles following cellular internalization (supplementary information Fig. S3). Excitation of 
the PS disrupts the membranes of intracellular vesicles, thereby triggering the release of 
internalized matter [23-25]. As described in the supplementary information (Fig. S4) we 
could visually confirm that PCI improves the intracytoplasmic siRNA delivery from dextran 
nanogels. In agreement with our earlier results we also observed a significant improvement 
in the extent of EGFP gene silencing when siEGFP loaded nanogels were used (data not 
shown).  
More importantly, we now wanted to test whether PCI, besides improving the 
magnitude of gene silencing, would also allow to induce a more sustained gene silencing by 
siRNA delivered from dextran nanogels. In most therapeutic applications up to now, PCI is 
applied at the same day as the actual transfection. To the best of our knowledge, there are 
no PCI reports available addressing the activation of PS at later time-points post-
transfection. Therefore we applied PCI at different time-points after transfecting the Huh-
7_EGFP cells with siRNA-nanogels (PCI applied at y days post-transfection is indicated as PCI 
ty) and analyzed the extent and duration of the gene silencing. The experimental protocols 
used in these experiments are summarized in supplementary information (Fig. S5). 
 
 
Fig. 5. EGFP expression as a function of time following transfection with siEGFP nanogels (DS 
5.2) in the absence (■) or presence (○) of PS following the experimental protocol described 
in Fig. S5 in supplementary information. The arrow indicates the time-point of PS activation 
and PS was added to the cells one day prior to illumination. The (light and dark) grey colored 
zones indicate the time window during which more than 50 % knockdown of EGFP was 
observed. (A) 25 µg/mL nanogels, PCI t0, (B) 25 µg/mL nanogels, PCI t2, (C) 50 µg/mL 
nanogels, PCI t2. Data points are mean values ± SD (n=3). Data points where EGFP expression 
is statistically different (PCI compared with absence of PCI) are denoted by * (p<0.01). 
 
As Fig. 5A shows, PCI t0 on dex-HEMA-co-TMAEMA nanogels (DS 5.2, 25 µg/mL) markedly 
enhanced the EGFP knockdown. Nevertheless, the stronger gene silencing was gradually lost 
as can be seen at day 9 and day 12 post-transfection. Surprisingly, though importantly, when 
transfecting the cells with a higher nanogel concentration (50 µg/mL) the PCI t0 protocol did 
not enhance the gene silencing outcome (data not shown), indicating the saturation of the 
RNAi pathway when 50 µg/mL was used. It seems that siRNA molecules additionally released 
into the cytoplasm by PCI treatment do not contribute to the RNAi effect but are merely 
diluted in the cell over time as a result of degradation and cell division. Hence, there is also 
no positive outcome on the longevity of the RNAi effect. To significantly prolong the RNAi 
effect, an additional siRNA dose will be needed at a later time following transfection. 
Therefore we further investigated whether delayed PCI could fulfil these requirements.  
The results on the delayed PCI treatment (PCI t2) are summarized in Fig. 5B-C. At day 
3 post-transfection, being 24 h after photochemical treatment, a (significant) difference is 
observed between PCI treated and non-treated cells when 25 µg/mL nanogels were applied 
on the cells (Fig. 5B), but not when 50 µg/mL nanogels were applied (Fig. 5C). At later time 
points the gene silencing remains substantially enhanced for the 25 µg/mL transfected cells. 
These results clearly indicate that 2 days following transfection, PCI is still able to release 
some of the siRNA loaded nanogels into the cytosol. Most likely, newly formed PS containing 
vesicles can interact/fuse with pre-existing vesicles still containing siRNA nanogels thus 
explaining the additional RNAi effect following PS activation at t2. 
This result also suggests that the prolonged residence time of siRNA duplexes in 
intracellular vesicles (e.g. endolysosomes) is not detrimental at least for a fraction of the 
internalized siRNAs. Nonetheless, as seen for PCI t0, PCI t2 can only moderately lengthen the 
EGFP knockdown (Fig. 5B).  
Ideally an additional siRNA dose should be delivered in the cytosol at the time-point 
when maintaining the gene silencing effect becomes critical, i.e. ~6 days under our 
experimental conditions as shown in Fig. 5. In fast dividing cell lines it is conceivable that the 
intracellular dilution of internalized nanogels, due to cell division, will set the limit for a 
delayed PCI treatment as sufficient nanogels should remain in the cells at the time of PCI. 
We studied the dilution of nanogels in Huh-7_EGFP cells using Alexa Fluor®647 (AF647)-
labelled cationic dex-MA nanogels (DS 5.9, 50 µg/mL). As Fig. 6A shows, the fluorescently 
labelled nanogels became easily internalized by hepatoma cells. The effect of cellular 
dilution could be clearly illustrated by flow cytometry measurements. Figure 6B reveals a 
fast decrease over time of the average intracellular fluorescence due to the distribution of 
the nanogel particles over the daughter cells. At day 6 post-transfection, only ~8% of the 
initial average fluorescence remained although still 97% of the cells were positive for AF647 
fluorescence. 
 
 
Fig. 6. (A) Confocal fluorescence image of Alexa Fluor®647 (AF647) labelled dex-MA-co-
TMAEMA/AEMA nanogels (50 µg/mL, see Supplementary Information) internalized by Huh-
7_EGFP cells following 4 h of incubation. Nuclei are stained with DAPI (blue color). (B) 
Average Alexa Fluor®647 fluorescence of the cells (bars) and percentage of Alexa Fluor®647 
positive cells (○) as a function of time after applying the red labeled nanogels, as measured 
by flow cytometry (n=6).  
 
 
We therefore conducted a delayed PCI experiment on day 6 after transfection of Huh-
7_EGFP cells with siRNA loaded dex-HEMA-co-TMAEMA nanogels (DS 5.2, 50  µg/mL; see Fig. 
S6 in supplementary information for experimental protocol). Lipofectamine™RNAiMAX was 
used as a control (Fig. 7). Also note that the PCI_t6 experiment was performed with Dicer 
substrate siRNAs (DsiRNAs), chemically modified with 2’-O-methylribonucleotides [33], to 
provide additional stability against nuclease attack. 
Without PCI (Fig. 7A), using both dex-HEMA-co-TMAEMA nanogels and 
Lipofectamine™RNAiMAX, the EGFP gene was silenced up to ~80% and this effect lasted for 
approximately 6 days after which the EGFP expression gradually recovered to steady state. 
Remarkably, the application of PCI 6 days post-transfection (Fig. 7B) substantially prolonged 
the gene silencing in cells transfected with the dextran nanogels, maintaining >50% EGFP 
downregulation for up to 2 weeks in the fast dividing cancer cells. This is much longer than 
the RNAi effect that is usually obtained in these cell lines [14]. It can be anticipated that 
when applying the same delivery strategy on cells with a slower division rate, even stronger 
effects could emerge. 
 
 
 
Fig. 7. (A) Application of PCI 6 days post-transfection (PCI t6) on cells transfected with dex-
HEMA-co-TMAEMA (DS 5.2; 50 µg/mL) nanogels (●) and Lipofectamine™ RNAiMAX (○). (A) 
EGFP gene silencing as a function of time without PCI. (B) EGFP suppression as a function of 
time with the application of PCI. The (light and dark) grey colored zones indicate the time 
window during which more than 50 % knockdown of EGFP was observed. Data points where 
EGFP expression is statistically different compared with the same time-points in the 
transfection without PCI are denoted by * (p<0.005). 
 
 
In contrast and evenly remarkable, this beneficial effect was not observed for the 
Lipofectamine™RNAiMAX transfected cells. Also note that PCI t2 did not have a beneficial 
effect at all on the RNAi kinetics for Lipofectamine™RNAiMAX (supplementary 
information_Fig. S7). These data clearly reflect the difference in mechanism of siRNA 
delivery between a polymeric matrix type carrier (e.g. nanogels) and a lipid vesicle type 
carrier.  Liposomal carriers most likely give rise to an immediate release of the loaded siRNA 
in the cytosol due to fusion with the endosomal membrane and even with the 
plasmamembrane [30]. Opposite to our nanogels, which remain trapped inside intracellular 
vesicles, liposomes do not create an intracellular depot of siRNA, thus making these 
transfection agents refractive towards a PCI controlled siRNA release.  
It is important to note that in Fig. 7 chemically modified dicer substrate siRNAs (DsiRNAs) 
were used. DsiRNAs potentially show improved silencing efficiency and duration compared 
to conventional 21 mer siRNAs. This is thought to originate from Dicer recognition and 
cleavage which could improve their incorporation into RISC. Moreover, the introduction of 
chemical modifications to decrease their susceptibility for nuclease degradation could also 
have its implications on the persistence of the RNAi effect relative to unmodified duplexes 
[13]. Especially following a prolonged incubation in the (nuclease rich) intracellular 
environment, the use of chemically modified DsiRNAs could be an advantage over 
unmodified 21 mer siRNAs.  
On the other hand, also the electrostatic incorporation of siRNAs in dextran nanogel 
particles could provide additional protection to nuclease attack. At this moment we do not 
have conclusive data on the degradation of the DS 5.2 nanogels in the endolysosomal 
compartment. Early data in the literature [28] state that hydrolysis of the dex-HEMA 
carbonate ester is minimal at the acidic pH found in endolysosomes (pH ~4.5-5) and as a 
consequence the nanogel degradation will be substantially slower than at neutral pH. It still 
remains to be evaluated if after 6 days siRNA nanogels or decomplexed (free) siRNA is 
released into the cytoplasm. 
 
Conclusion 
 
Photochemical internalization is able to liberate a fraction of the siRNA-nanogels trapped in 
(endocytic) vesicles, resulting in an additional siRNA dose that is released in the cell 
cytoplasm. PCI has the ability to substantially enhance the duration of EGFP knockdown, 
especially when PCI is applied at the time-point when maintaining the RNAi effect becomes 
critical. Delayed PCI therefore is a potential strategy to prolong the therapeutic effect in the 
case when endosomal escape is the effect-limiting step, by applying intracellular vesicles as 
depot systems for PCI controlled release. Moreover, this strategy enables longer RNAi 
effects to be obtained with one single dose of siRNA nanocarrier, thereby avoiding the need 
for a second administration to obtain the same effect longevity. The incorporation of the 
photosensitizing agent into the nanocarrier itself could be a valuable addition to this concept 
[34]. The siRNA impregnated nanogels are scheduled to be tested in vivo following local 
injection in combination with PCI at different time-points following administration. 
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